Zain Ebrahim
Stock Analyst at J.P. Morgan
(2.01)
# 3,331
Out of 5,126 analysts
42
Total ratings
52.2%
Success rate
1.1%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,700p | 1,913p | -11.11% | 33 | Nov 3, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Buy | CHF 85.00 → CHF 90.00 | CHF 80.50 | +11.80% | 4 | Sep 10, 2026 | |
| EPA: EAPI Euroapi S.A. | Reiterated: Hold | €1.70 | €0.78 | +117.95% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Reiterated: Buy | 2,400p → 2,000p | 1,660p | +20.48% | 2 | Mar 3, 2026 | |
| LON: OXB Oxford Biomedica plc | Reiterated: Hold | 550p | 545p | +0.92% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 675.00 | CHF 665.60 | n/a | 1 | Jul 28, 2025 |
GSK plc
Nov 3, 2026
Reiterated: Sell
Price Target: 1,700p
Current: 1,913p
Upside: -11.11%
Bachem Holding AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 85.00 → CHF 90.00
Current: CHF 80.50
Upside: +11.80%
Euroapi S.A.
May 13, 2026
Reiterated: Hold
Price Target: €1.70
Current: €0.78
Upside: +117.95%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Reiterated: Buy
Price Target: 2,400p → 2,000p
Current: 1,660p
Upside: +20.48%
Oxford Biomedica plc
Dec 8, 2025
Reiterated: Hold
Price Target: 550p
Current: 545p
Upside: +0.92%
Lonza Group AG
Jul 28, 2025
Reiterated: Buy
Price Target: CHF 675.00
Current: CHF 665.60
Upside: n/a